Yubo International Biotech Limited (YBGJ)
USD 0.08
(56.51%)
USD 0.08
(56.51%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 772.27 Thousand USD | -71.04% |
| 2021 | 2.66 Million USD | 349.83% |
| 2020 | -1.06 Million USD | -183.32% |
| 2019 | 1.28 Million USD | 11.49% |
| 2018 | 1.14 Million USD | 23.02% |
| 2017 | 934 Thousand USD | 16.02% |
| 2016 | 805 Thousand USD | 18.21% |
| 2015 | 681 Thousand USD | 21.61% |
| 2014 | 560 Thousand USD | 20.69% |
| 2013 | 464 Thousand USD | 21.15% |
| 2012 | 383 Thousand USD | 25.99% |
| 2011 | 304 Thousand USD | 35.11% |
| 2010 | 225 Thousand USD | 43.31% |
| 2009 | 157 Thousand USD | 67.02% |
| 2008 | 94 Thousand USD | 193.75% |
| 2007 | 32 Thousand USD | 165.31% |
| 2006 | -49 Thousand USD | -8.89% |
| 2005 | -45 Thousand USD | 83.08% |
| 2004 | -266 Thousand USD | 65.18% |
| 2003 | -764 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 555.3 Thousand USD | -12.8% |
| 2023 Q1 | 636.81 Thousand USD | -17.54% |
| 2022 Q1 | 2.76 Million USD | 3.6% |
| 2022 Q3 | 2.11 Million USD | -10.42% |
| 2022 FY | 772.27 Thousand USD | -71.04% |
| 2022 Q2 | 2.35 Million USD | -14.57% |
| 2022 Q4 | 772.27 Thousand USD | -63.47% |
| 2021 Q4 | 2.66 Million USD | 16.96% |
| 2021 Q3 | 2.27 Million USD | 15.63% |
| 2021 FY | 2.66 Million USD | 349.83% |
| 2021 Q1 | 1.81 Million USD | 270.15% |
| 2021 Q2 | 1.97 Million USD | 8.56% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | 1.47 Million USD | 0.0% |
| 2020 FY | -1.06 Million USD | -183.32% |
| 2020 Q4 | -1.06 Million USD | -172.51% |
| 2020 Q1 | - USD | -100.0% |
| 2019 Q2 | 1.28 Million USD | 0.0% |
| 2019 Q1 | 1.28 Million USD | 2.64% |
| 2019 Q4 | 1.37 Million USD | 2.22% |
| 2019 FY | 1.28 Million USD | 11.49% |
| 2019 Q3 | 1.34 Million USD | 5.31% |
| 2018 Q4 | 1.24 Million USD | 2.3% |
| 2018 Q3 | 1.22 Million USD | 0.0% |
| 2018 Q2 | - USD | -100.0% |
| 2018 Q1 | 1.14 Million USD | 9.12% |
| 2018 FY | 1.14 Million USD | 23.02% |
| 2017 Q1 | 934 Thousand USD | 4.24% |
| 2017 FY | 934 Thousand USD | 16.02% |
| 2017 Q3 | 1.01 Million USD | 0.0% |
| 2017 Q4 | 1.05 Million USD | 3.44% |
| 2017 Q2 | - USD | -100.0% |
| 2016 Q1 | 805 Thousand USD | 3.34% |
| 2016 FY | 805 Thousand USD | 18.21% |
| 2016 Q4 | 896 Thousand USD | 3.11% |
| 2016 Q3 | 869 Thousand USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 FY | 681 Thousand USD | 21.61% |
| 2015 Q1 | 681 Thousand USD | 2.87% |
| 2015 Q4 | 779 Thousand USD | 0.0% |
| 2015 Q2 | 681 Thousand USD | 0.0% |
| 2014 Q1 | 560 Thousand USD | 3.7% |
| 2014 Q3 | 625 Thousand USD | 11.61% |
| 2014 FY | 560 Thousand USD | 20.69% |
| 2014 Q2 | 560 Thousand USD | 0.0% |
| 2014 Q4 | 662 Thousand USD | 5.92% |
| 2013 Q1 | 464 Thousand USD | 4.74% |
| 2013 Q4 | 540 Thousand USD | 0.0% |
| 2013 FY | 464 Thousand USD | 21.15% |
| 2013 Q3 | - USD | 100.0% |
| 2013 Q2 | -12 Thousand USD | -102.59% |
| 2012 Q1 | 383 Thousand USD | 6.09% |
| 2012 Q2 | 383 Thousand USD | 0.0% |
| 2012 Q3 | 425 Thousand USD | 10.97% |
| 2012 Q4 | 443 Thousand USD | 4.24% |
| 2012 FY | 383 Thousand USD | 25.99% |
| 2011 FY | 304 Thousand USD | 35.11% |
| 2011 Q2 | 304 Thousand USD | 0.0% |
| 2011 Q3 | 347 Thousand USD | 14.14% |
| 2011 Q4 | 361 Thousand USD | 4.03% |
| 2011 Q1 | 304 Thousand USD | 7.04% |
| 2010 Q3 | 268 Thousand USD | 19.11% |
| 2010 FY | 225 Thousand USD | 43.31% |
| 2010 Q4 | 284 Thousand USD | 5.97% |
| 2010 Q1 | 225 Thousand USD | 0.0% |
| 2010 Q2 | 225 Thousand USD | 0.0% |
| 2009 FY | 157 Thousand USD | 67.02% |
| 2009 Q1 | 157 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q1 | 94 Thousand USD | 0.0% |
| 2008 FY | 94 Thousand USD | 193.75% |
| 2007 Q1 | 32 Thousand USD | 0.0% |
| 2007 FY | 32 Thousand USD | 165.31% |
| 2006 FY | -49 Thousand USD | -8.89% |
| 2006 Q1 | -49 Thousand USD | 0.0% |
| 2005 FY | -45 Thousand USD | 83.08% |
| 2005 Q1 | -45 Thousand USD | 0.0% |
| 2004 Q1 | -266 Thousand USD | 0.0% |
| 2004 FY | -266 Thousand USD | 65.18% |
| 2003 FY | -764 Thousand USD | 0.0% |
| 2003 Q1 | -764 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 479.63 Thousand USD | -61.015% |
| Ansell Limited | -54.99 Million USD | 101.404% |
| Ansell Limited | -55.1 Million USD | 101.402% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | -36.49 Million USD | 102.116% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -105.1 Thousand USD | 834.79% |
| Psykey, Inc. | 634.59 Thousand USD | -21.697% |
| ConvaTec Group Plc | 1.2 Billion USD | 99.936% |
| ConvaTec Group Plc | 1.2 Billion USD | 99.936% |
| Encision Inc. | 1.29 Million USD | 40.166% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 66.549% |
| Innovative MedTech Inc. | 1.76 Million USD | 56.238% |
| LifePoint, Inc. | -3.26 Million USD | 123.66% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | 84.253% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | 64.279% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -43.3 Thousand USD | 1883.39% |
| Reflect Scientific, Inc. | -1.03 Million USD | 174.594% |
| SmileDirectClub, Inc. | 778.67 Million USD | 99.901% |
| Sector 10, Inc. | 163 Thousand USD | -373.791% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 100.185% |
| SheerVision, Inc. | 57.34 Thousand USD | -1246.63% |
| United Health Products, Inc. | 660.56 Thousand USD | -16.911% |
| Vasamed, Inc. | 22.12 Thousand USD | -3391.0% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | 70.649% |